Samjin Pharmaceutical Collaborates with Oncobix on R&D for Cancer and Fibrosis Intractable Disease Treatments
[Asia Economy Reporter Lee Gwan-joo] Samjin Pharmaceutical announced on the 19th that it has signed a strategic business agreement with Oncobix, a company specializing in innovative new drug development, for the research and development of treatments for cancer and fibrotic intractable diseases.
Through this agreement, Samjin Pharmaceutical will conduct research on the synthesis of derivatives of new drug candidates for cancer and fibrosis, as well as formulation and manufacturing quality control (CMC). Oncobix will provide design and synthesis-related consulting and research for deriving new drug candidates based on its innovative new drug development platform, 'TOFPOMICS.'
Samjin Pharmaceutical's Magok Research Center continues to accumulate research and development infrastructure through innovative new drug development for diseases with high unmet medical needs such as cancer, fibrotic diseases, ophthalmic diseases, degenerative brain diseases, and autoimmune diseases, as well as related national projects and industry-academia-research institute joint research.
Lee Soo-min, head of Samjin Pharmaceutical's Research Center, said, "The success of innovative new drug development is so challenging and has a low feasibility that overcoming it can be considered a benchmark. However, it is an inevitable and urgent task that must be achieved to improve human health. We will combine over 30 years of research and development know-how and cutting-edge R&D infrastructure with Oncobix's proprietary new drug development platform and expertise in developing treatments for intractable diseases, thereby increasing the likelihood of success in innovative new drug development."
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Domestic Banks' Q1 Net Profit at 6.7 Trillion Won...Down 3.9%
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Kim Sung-eun, CEO of Oncobix, stated, "Intractable diseases have short life expectancy and lack appropriate treatments, making new drug development urgent. Through this agreement, we will strive to develop next-generation innovative new drugs that can provide solutions for cancer and fibrotic intractable diseases through mutual synergy with Samjin Pharmaceutical."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
